CD8A and melanoma: In three groups of patients treated with PD1 inhibitor, anti-CTLA-4, and combination therapy, CD8+ T cells were found to be a key component of the immune checkpoint inhibitory mechanism, which is abundant in melanoma and closely related to tumor depletion.